International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Stability-Indicating Liquid Chromatographic Method for the Determination of Bendamustine Hydrochloride in Parenterals

Author Affiliations

  • 1Department of Pharmaceutical Analysis and Quality Assurance, GITAM Institute of Pharmacy, Visakhapatnam, INDIA

Res.J.chem.sci., Volume 2, Issue (9), Pages 72-78, September,18 (2012)


A stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of Bendamustine hydrochloride in injectables. Reversed-phase chromatography was performed on Shimadzu Model CBM-20A/20 Alite, equipped with SPD M20A prominence photodiode array detector using C18 (250 mm 4.6 mm, 5 m particle size) column with acetonitrile: tetra butyl ammonium hydrogen sulphate (80:20, V/V) as mobile phase at a flow rate of 0.8 mL/min. with UV detection at 233 nm. Linearity was observed in the concentration range of 1.0200 g/mL (R2 = 0.999) with regression equation y = 10691 x + 98237. The limit of quantitation (LOQ) and limit of detection (LOD) were found to be 0.812 and 0.268 g/mLrespectively. The forced degradation studies were performed by using HCl, NaOH, H2O2 etc. Bendamustine hydrochloride is more sensitive towards elevated temperatures (80C) in comparison to acidic and oxidative conditions but very much resistant towards alkaline conditions. The method was validated as per ICH guidelines. The RSD for intra-day (0.14-0.32) and inter-day (0.47-0.66) precision were found to be less than 1 %. The percentage recovery was in good agreement with the labeled amount in the pharmaceutical formulations and the method is simple, specific, precise and accurate for the determination of Bendamustine hydrochloride in pharmaceutical formulations.


  1. Neil M.J.O., The Merck Index, Merck Research Laboratories, Whitehouse Station, NJ (2006)
  2. Friedberg J. W., Cohen P., Chen L., et al., Bendamustine in Patients with Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results from a Phase II Multicenter, Single-Agent Study, J. Clinical Oncology, 26(2), 204-210 (2008)
  3. Lissitchkov T., Arnaudov G., Peytchev D., Merkle Kh., Phase-I/II Study to Evaluate Dose Limiting Toxicity, Maximum Tolerated Dose, and Tolerability of Bendamustine HCl in Pre-Treated Patients with B-Chronic Lymphocytic Leukaemia (Binet Stages B and C) Requiring Therapy, J. Cancer Research and Clinical Oncology132(2), 99-104 (2006)
  4. Teichert J., Sohr R., Baumann F., Hennig L., et al., Synthesis and Characterization of Some New Phase II Metabolites of the Alkylator Bendamustine and their Identification in Human Bile, Urine, and Plasma from Patients with Cholangiocarcinoma,Drug Metabolism and Disposition, 33(7), 984-992 (2005)
  5. Matt Kalaycio, Clinical Experience with Bendamustine : A new treatment for patients with chronic lymphocytic leukemia, Clin Leukemia, 2(4), 223-229 (2008)
  6. Teichert J., Baumann F., Chao Q., Franklin C.,et al., Characterization of two phase I metabolites of Bendamustine in human liver microsomes and in cancer patients treated with Bendamustine hydrochloride, Cancer Chemother. Pharmacol, 59(6), 759-770 (2007)
  7. Rasschaert M., Schrijvers D., Van den Brande J. et al., A Phase I Study of Bendamustine Hydrochloride Administered Once Every Three Weeks in Patients With Solid Tumors, British Journal of Cancer, 96, 16921698 (2007)
  8. Preiss R., Sohr R., Matthias M., Brockmann B., Huller H., The Pharmacokinetics of Bendamustine (Cytostasane) in Humans, Pharmazie, 40, 782-784 (1985)
  9. Ivanka Pencheva, Anita Bogomilova, Neli Koseva, Danka Obreshkova, Kolio Troev, HPLC Study on the Stability of Bendamustine Hydrochloride Immobilized onto Polyphosphoesters, J. Pharm. Biomed. Analysis, 48(4), 11431150 (2008)
  10. Mathrusri Annapurna M., Pavani S., Anusha S., Harika Mahanti and Venkatesh B., New Analytical Methods for the Determination of Bendamustine Hydrochloride - An Anti-Neoplastic Drug, Journal of Chemical and Pharmaceutical Research, 4(3), 1696-1701 (2012)
  11. ICH Validation of analytical procedures: Text and methodology Q2(R1), International Conference on Harmonization, (2005)
  12. ICH Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization, (2003)